{"id":{"repo_id":"unr","oai_identifier":"oai:scholarwolf.unr.edu:11714/3078"},"canonical_url":"https://search.dev.ndltd.org/etd/unr/oai:scholarwolf.unr.edu:11714/3078","repository":{"repo_id":"unr","name":"University of Nevada - Reno","base_url":"https://scholarwolf.unr.edu/server/oai/request"},"display":{"title":"Synthesis of Novel Unsymmetrical CADA Analogues to Isolate and Characterize Their Site of Action","abstract":"CADA analogues inhibit human immunodeficiency viral infection by disrupting the co-translational translocation of CD4, thereby down-regulating its expression. Although CADA analogues are known to act by this mechanism, their specific biomolecular target remains unknown. This project describes the synthesis of two novel analogues that will be used to isolate and identify their biological target through bioaffinity chromatography. In addition, four other novel analogues are synthesized to test for CD4 down-regulation activity. Finally, this project describes the synthesis of an intermediate that will be used in a new proposed synthetic pathway for unsymmetrical CADA analogues.","abstract_html":"CADA analogues inhibit human immunodeficiency viral infection by disrupting the co-translational translocation of CD4, thereby down-regulating its expression. Although CADA analogues are known to act by this mechanism, their specific biomolecular target remains unknown. This project describes the synthesis of two novel analogues that will be used to isolate and identify their biological target through bioaffinity chromatography. In addition, four other novel analogues are synthesized to test for CD4 down-regulation activity. Finally, this project describes the synthesis of an intermediate that will be used in a new proposed synthetic pathway for unsymmetrical CADA analogues.","abstract_has_math":false,"creators":["Pflug, Nicholas C."],"institution":null,"degree_name":null,"degree_level":"Master's Degree","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Bell, Thomas W."],"committee_chairs":[],"committee_members":["Jeffrey, Christopher S.","Schooley, David A."],"year":2013,"date_issued":"2013","date_published":"2013","updated_at":"2026-07-27T21:46:08Z","subjects":[],"languages":[],"rights":["In Copyright(All Rights Reserved)"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11714/3078","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Bell, Thomas W."]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Jeffrey, Christopher S.","Schooley, David A."]},{"key":"dc:creator","label":"Author","values":["Pflug, Nicholas C."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2018-05-01T12:26:20Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2018-05-01T12:26:20Z"]},{"key":"dc:date.issued","label":"Date","values":["2013"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Master's Degree"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:rights","label":"Dc Rights","values":["In Copyright(All Rights Reserved)"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11714/3078"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["CADA analogues inhibit human immunodeficiency viral infection by disrupting the co-translational translocation of CD4, thereby down-regulating its expression. Although CADA analogues are known to act by this mechanism, their specific biomolecular target remains unknown. This project describes the synthesis of two novel analogues that will be used to isolate and identify their biological target through bioaffinity chromatography. In addition, four other novel analogues are synthesized to test for CD4 down-regulation activity. Finally, this project describes the synthesis of an intermediate that will be used in a new proposed synthetic pathway for unsymmetrical CADA analogues."]},{"key":"dc:format","label":"Dc Format","values":["PDF"]},{"key":"dc:title","label":"Title","values":["Synthesis of Novel Unsymmetrical CADA Analogues to Isolate and Characterize Their Site of Action"]}]}],"canonical_facts":{"dc:contributor.advisor":["Bell, Thomas W."],"dc:contributor.committeemember":["Jeffrey, Christopher S.","Schooley, David A."],"dc:creator":["Pflug, Nicholas C."],"dc:date.accessioned":["2018-05-01T12:26:20Z"],"dc:date.available":["2018-05-01T12:26:20Z"],"dc:date.issued":["2013"],"dc:description.abstract":["CADA analogues inhibit human immunodeficiency viral infection by disrupting the co-translational translocation of CD4, thereby down-regulating its expression. Although CADA analogues are known to act by this mechanism, their specific biomolecular target remains unknown. This project describes the synthesis of two novel analogues that will be used to isolate and identify their biological target through bioaffinity chromatography. In addition, four other novel analogues are synthesized to test for CD4 down-regulation activity. Finally, this project describes the synthesis of an intermediate that will be used in a new proposed synthetic pathway for unsymmetrical CADA analogues."],"dc:format":["PDF"],"dc:identifier.uri":["http://hdl.handle.net/11714/3078"],"dc:rights":["In Copyright(All Rights Reserved)"],"dc:title":["Synthesis of Novel Unsymmetrical CADA Analogues to Isolate and Characterize Their Site of Action"],"dc:type":["Thesis"],"thesis:degree_level":["Master's Degree"]},"updated_at":"2026-07-27T21:46:08Z"}